Biogen Idec/PDL BioPharma Plan To Study Daclizumab As Monotherapy For MS
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II monotherapy trial for the monoclonal antibody will initiate in the second half of 2007, PDL tells “The Pink Sheet” DAILY.